Stock MYCOF MYDECINE INNOVATIONS GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Mydecine Innovations Group Inc.

Equities

MYCOF

CA62849F2008

Market Closed - OTC Markets
Other stock markets
 08:12:38 28/06/2024 pm IST 		5-day change 1st Jan Change
0.01 USD 0.00% Intraday chart for Mydecine Innovations Group Inc. +31.58% -32.89%
01/05 Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding CI
23/02 Mydecine Innovations Closes Partial Debt Settlement MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mydecine Innovations Group Receives Notice of Allowance from USPTO For MYCO-005 Compound
MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Mydecine Innovations Group Provided Q4 2023 Business Update
MT
Mydecine Innovations Group Brief: Announced Admission to Trading on AQSE Growth Market in London, UK and First Day of Dealings
MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Mydecine Innovations Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Mydecine Innovations Group Inc. Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting Emp Analogues
CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Pangenomic Health Inc. completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).
CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Pangenomic Health Inc. signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.
CI
Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs
CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs
CI
Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
CI
Mydecine Innovations Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Mydecine Innovations Group Inc. Receives Conditional IRB Approval for Phase 2B Smoking Cessation Study
CI
Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study
CI
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
CI
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYCOF Stock
  4. News Mydecine Innovations Group Inc.
  5. Highlights